Phase III washout for AdociaAdocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products. more ➔
AZ unloads antibiotics to Pfizer24.08.2016 – Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZenecas antibiotics for a cool US$1.5bn. With the divestment, … more ➔
€87m for Cambridge Cluster fund23.08.2016 – Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment … more ➔
Priority review for Genmabs Darzalex?19.08.2016 – Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental … more ➔
Post-Brexit EU funding securedPhilip Hammond, the UKS chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UKs departure … more ➔
Epigenomics considers US listingBack in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the … more ➔
Genmab in HIV antibody dealDanish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m. more ➔
Ploughing ahead after Phase III setbackHungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study … more ➔
Alzheimers vaccine clears Phase IAraclon Biotechs Alzheimers vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimers Association … more ➔
EMA keeps approval speedway openAfter a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to explore the concept further and will continue to accept proposals. more ➔
